The Office for Product Safety and Standards (OPSS) has opened a dedicated cosmetics sandbox bioengineered ingredients initiative for businesses working with novel, biology-based cosmetic inputs. For manufacturers, importers and responsible persons, this is a practical opportunity to address regulatory uncertainty before products reach the market. The programme is designed to support innovation while helping ensure consumers remain protected under the GB Cosmetics Regulation.
What is the cosmetics sandbox bioengineered ingredients initiative?
The cosmetics sandbox bioengineered ingredients is OPSS’s first sandbox and forms part of a wider Product Regulation Sandbox programme. It focuses on innovative cosmetic ingredients developed using bioengineering approaches, often referred to as engineering biology. Rather than offering a shortcut to approval, the sandbox creates structured dialogue between businesses and OPSS regulatory and scientific experts.
Expressions of Interest are now being accepted from businesses that would benefit from focused regulatory engagement. The goal is to explore challenges linked to the development and commercialisation of novel cosmetic ingredients. Participants can raise questions about safety assessment, regulatory interpretation and evidence expectations in a more collaborative setting.
Why take part in the OPSS sandbox
Bioengineered cosmetic ingredients can raise complex questions that do not always fit neatly into existing guidance. A fermentation-derived active, a cell-cultured molecule or an ingredient produced through precision biology may require tailored safety reasoning. The sandbox offers a route to discuss those questions directly with OPSS experts.
For many teams, the sandbox is most valuable when scientific and regulatory questions are still open. Early dialogue can help identify whether existing safety assessment methods are appropriate, what data may need to be generated, and how to frame evidence in a way that aligns with the GB Cosmetics Regulation. It is not a replacement for a safety assessor, a responsible person or a full product safety assessment, but it can reduce guesswork during development.
Selected businesses will have the opportunity to:
- Engage directly with OPSS regulatory and scientific experts.
- Discuss regulatory considerations relevant to their specific innovation.
- Explore approaches to generating and presenting safety evidence.
- Gain greater confidence in navigating existing regulatory requirements.
- Raise questions and challenges associated with bringing innovative products to market.
OPSS also benefits from the sandbox by gaining insight into opportunities and challenges associated with bioengineered cosmetic ingredients. This insight may help inform future regulatory thinking without changing current legal obligations.
Who should apply to the cosmetics sandbox bioengineered ingredients programme
OPSS is interested in hearing from businesses that develop, manufacture or use bioengineered cosmetic ingredients. The programme is particularly relevant where teams have encountered regulatory questions, safety assessment challenges or uncertainty in applying the GB Cosmetics Regulation.
This may include raw material innovators, cosmetic manufacturers, brand owners, importers and responsible persons. The common factor is a real regulatory question or safety assessment issue that would benefit from focused engagement. Applicants do not need to have a finished product, but they should be able to describe the technology, its intended cosmetic use and the stage of development.
How to prepare a strong expression of interest
OPSS asks applicants to provide a short description of their organisation and a case study. The organisation description should include the type, size and maturity of the business, as well as its role within the cosmetics value chain. This helps OPSS understand whether the sandbox is the right forum for the specific question.
The case study should cover several practical areas:
- The ingredient, product or technology under development.
- Its intended cosmetic use and stage of development.
- The engineering biology approach being used and a summary process flowchart including safety steps.
- Any regulatory questions, uncertainties or challenges encountered.
- Relevant safety assessment considerations and summary safety data, including the use of New Approach Methodologies where applicable.
- Any previous engagement with other regulators, whether local or national.
- How participation in the sandbox could support the organisation.
As a guide, Expressions of Interest should provide enough information for OPSS to understand the innovation and the regulatory questions being raised. This will typically be around 1,000 words. Supporting information such as technical summaries, safety dossiers or other relevant documentation is welcomed where available.
What to focus on when describing bioengineered ingredients
Because the sandbox covers bioengineered cosmetic ingredients, it helps to be precise about the production method and the safety steps built into that process. OPSS asks for a summary process flowchart including safety steps, so applicants should think about the key stages from starting material to finished cosmetic ingredient.
Where possible, describe how the ingredient is characterised, how impurities or residual materials are controlled, and how the safety data support the intended cosmetic use. If New Approach Methodologies have been used, explain what they cover and where there may still be evidence gaps. A clear description of the production process and the associated safety reasoning gives OPSS a stronger basis for focused feedback.
UK and EU compliance context for cosmetic teams
The cosmetics sandbox bioengineered ingredients initiative is grounded in the GB Cosmetics Regulation. It is an OPSS-led UK programme, so it does not replace EU compliance obligations or the EU Cosmetics Regulation. Businesses placing products in both Great Britain and the EU still need to manage separate regulatory frameworks, dossiers and responsible person arrangements.
For companies working across markets, a bioengineered ingredient may require different evidence strategies depending on the jurisdiction. UK and EU safety assessors may both ask for robust data, but the engagement routes can differ. That makes it important to maintain clear documentation and understand which questions relate to GB requirements and which relate to EU requirements.
Teams should also consider how existing cosmetic compliance services across the EU and UK can support dossier preparation, responsible person duties and regulatory gap analysis. While the sandbox provides a valuable UK engagement channel, it does not remove the need for complete compliance records in either market.
Practical actions for businesses considering the sandbox
Before submitting an Expression of Interest, regulatory professionals should map the specific uncertainties they want to discuss. A focused case study is more useful than a general description of the technology. Identify where the GB Cosmetics Regulation feels unclear, where safety evidence is difficult to generate, or where a New Approach Methodology may need further justification.
It is also sensible to gather the supporting material OPSS may need. This could include process flowcharts, preliminary safety data, technical summaries or records of previous regulatory contact. The application does not need to be a finished safety dossier, but it should give OPSS enough detail to understand the innovation and the regulatory obstacle.
If you are unsure whether the cosmetics sandbox bioengineered ingredients is suitable for your organisation, you can contact OPSS at OPSS.EngBio@businessandtrade.gov.uk. The same email address is used for submitting Expressions of Interest and supporting information.
What to monitor after submitting an expression of interest
The Expression of Interest window is open until 4 December 2026. OPSS will review submissions and use them to identify case studies and topics for further exploration through the cosmetics sandbox bioengineered ingredients programme. Applicants should not expect immediate feedback during the open period.
OPSS aims to contact applicants within three months of the closing date with an update on the outcome of their submission and any next steps. This means businesses should plan for a waiting period after submission and continue their internal compliance work in parallel.
It is also worth monitoring the broader Product Regulation Sandbox collection on GOV.UK. Future sandboxes or related guidance may address adjacent product areas. For businesses working with bioengineered ingredients, early monitoring of OPSS communications can help teams prepare for any emerging regulatory expectations.
Preparing for a more collaborative compliance path
The OPSS sandbox is not an alternative to product safety assessment or compliance. It is a structured engagement mechanism for resolving uncertainty around novel bioengineered cosmetic ingredients. Businesses that use the opportunity effectively will arrive with clear questions, relevant safety data and a realistic understanding of their obligations under the GB Cosmetics Regulation.
For responsible persons, safety assessors and regulatory professionals, the key is to combine internal scientific rigour with proactive dialogue. The sandbox can help reduce ambiguity, but robust safety evidence and complete documentation remain the foundation of market access.
Engage early, document safety evidence clearly, and use OPSS dialogue to reduce regulatory uncertainty.